Can Aarti Drugs Maintain Its Recovery?

Aarti Drugs Q2 FY26 results indicate strong operational recovery, higher realization, and improved margin profile across API and formulation businesses.

Can Aarti Drugs Maintain Its Recovery Amid Raw Material Price Volatility?

About Aarti Drugs

Aarti Drugs Ltd is a leading pharmaceutical manufacturer specializing in active pharmaceutical ingredients (APIs), intermediates, and specialty chemicals. The company is part of the Aarti Group and serves both domestic and export markets with over 50 therapeutic categories.

The company witnessed healthy growth driven by recovery in API prices and export demand, while cost optimization supported profitability improvement.

Financial Highlights (Q2 FY26)

Metric	Q2 FY26	YoY	QoQ
Revenue	₹580 Cr	+7%	+5%
EBITDA	₹75 Cr	+26%	+8%
EBITDA Margin	13%	vs 11%	vs 12.3%
Net Profit	₹42 Cr	+1,290%	+9%

Revenue ₹580 Cr — supported by improved API realizations and higher export share.

EBITDA ₹75 Cr — benefited from lower input costs and better product mix.

EBITDA Margin 13% — expanded on operational leverage and price recovery.

Net Profit ₹42 Cr — up sharply due to base effect and efficiency gains.

Short-term traders can monitor setups using Nifty Derivative Tip for sector-linked movements.

Peer Comparison

Company	EBITDA Margin	YoY Change
Aarti Drugs	13%	+2 pp
Granules India	15%	+1 pp
Suven Pharma	12%	Flat

Aarti Drugs demonstrates sustained improvement despite raw material volatility.

Strengths & Weaknesses

Strengths ✅ Strong API portfolio with global reach. ✅ Cost control and integration advantages.

Weaknesses ⚠️ Dependence on China for raw materials. ⚠️ Limited visibility in formulation scaling.

Operational stability and backward integration support margin resilience.

Opportunities & Threats

💡 Expanding API exports to regulated markets. 💡 New anti-infective and diabetic segments.

📉 Rising competition in key molecules. 📉 Raw material inflation risk.

Medium-term growth supported by diversification and new molecule launches.

Valuation & Investment View

• Short-term: Likely to trade in ₹495–₹525 zone.
• Medium-term: Margin expansion story intact.
• Long-term: Favourable valuation for patient investors.

Monitor broader pharma sentiment via BankNifty F&O Tip for volatility signals.

Investor Takeaway

Indian-Share-Tips.com’s Nifty Expert Gulshan Khera, CFP®, observes that Aarti Drugs’ strong recovery and margin profile make it an attractive midcap pharma pick. Explore more insights at Indian-Share-Tips.com, which is a SEBI Registered Advisory Services.

SEBI Disclaimer: The information provided in this post is for informational purposes only...

Aarti Drugs, Pharma Stocks, Midcap Pharma, API Exporters, NSE BSE Results